TODAY’S PAPER | April 24, 2026 | EPAPER

Netanyahu says he was successfully treated for prostate cancer

Says a malignant tumour found was removed with targeted treatment, leaving no trace now


Reuters April 24, 2026 1 min read
Israel’s Prime Minister Benjamin Netanyahu attends a ceremony commemorating Israel’s Remembrance Day for fallen soldiers, or Yom HaZikaron, at the Military Cemetery on Mount Herzl in Jerusalem April 21, 2026.PHOTO:REUTERS

Israeli Prime Minister Benjamin ‌Netanyahu said on Friday that he had received successful treatment for early-stage prostate cancer, without specifying when the treatment took place.

In a ​statement on social media, as his annual medical ​report was released, Netanyahu, 76, said an early ⁠stage malignant tumour had been discovered during a routine ​checkup. He said "targeted treatment" had removed "the problem" and left no ​trace of it.

According to the medical report, which otherwise said the prime minister was in good health, Netanyahu was treated with radiation ​therapy for early-stage prostate cancer. Neither the medical report ​nor Netanyahu said when the treatment occurred.

Read More: Netanyahu requests delay in his corruption trial testimony

Israel's longest-serving prime minister said ‌that ⁠he had delayed the release of the medical report by two months to prevent Iran from spreading "false propaganda against Israel".

In March, during the fighting with Iran, rumours that circulated ​on social ​media and ⁠aired on Iranian state media claimed that Netanyahu had died.

The Israeli leader recorded a ​video of himself visiting a Jerusalem cafe in ​March ⁠to refute the claims.

Netanyahu underwent surgery on his prostate in 2024 after he was diagnosed with a urinary tract infection resulting ⁠from ​a benign prostate enlargement. In 2023, ​he was fitted with a pacemaker.

Elections are due to be held in ​Israel by October.

COMMENTS

Replying to X

Comments are moderated and generally will be posted if they are on-topic and not abusive.

For more information, please see our Comments FAQ